Home | Welcome to Contract Pharma   
Last Updated Friday, April 18 2014
Print

Takeda Terminates Fasiglifam Development



By Kristin Brooks



Published December 30, 2013
Related Searches: Clinical Trials Development
Takeda Pharmaceutical Co. has decided to terminate development of fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. The company has worked with three independent panels regarding safety oversight, including the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program.
 
Following a review of the data emerging from all the clinical trials and in consultation with these panels, the company has decided that the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks, and has decided to voluntarily terminate development activities for fasiglifam.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On